Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
14(48%)
Results Posted
33%(1 trials)
Terminated
1(3%)

Phase Distribution

Ph phase_2
17
59%
Ph phase_1
5
17%
Ph phase_3
6
21%

Phase Distribution

5

Early Stage

17

Mid Stage

6

Late Stage

Phase Distribution28 total trials
Phase 1Safety & dosage
5(17.9%)
Phase 2Efficacy & side effects
17(60.7%)
Phase 3Large-scale testing
6(21.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

14

trials recruiting

Total Trials

29

all time

Status Distribution
Active(21)
Completed(3)
Terminated(2)
Other(3)

Detailed Status

Recruiting14
Not yet recruiting7
Completed3
unknown2
Withdrawn1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
14
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (17.9%)
Phase 217 (60.7%)
Phase 36 (21.4%)

Trials by Status

withdrawn13%
suspended13%
not_yet_recruiting724%
terminated13%
unknown27%
completed310%
recruiting1448%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT07057089Phase 2

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

Suspended
NCT07327229Phase 1

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
NCT05322577Phase 1

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Terminated
NCT07728019Phase 2

Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM

Not Yet Recruiting
NCT07723534Phase 2

Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers

Not Yet Recruiting
NCT07221357Phase 2

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Recruiting
NCT07221149Phase 2

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Recruiting
NCT05482893Phase 1

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Recruiting
NCT07622017Phase 2

KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer

Not Yet Recruiting
NCT07528209Phase 3

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

Recruiting
NCT07294664Phase 2

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

Recruiting
NCT03259035Phase 2

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

Completed
NCT07472868Phase 3

Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer

Not Yet Recruiting
NCT07297030Phase 2

SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer

Not Yet Recruiting
NCT05008809Phase 3

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
NCT07154316Phase 2

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

Recruiting
NCT06949111Phase 2

Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer(Neo-Color)

Recruiting
NCT07040098Phase 2

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Recruiting
NCT05646511Phase 3

TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer

Recruiting
NCT05379790Phase 1

Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin

Completed

Drug Details

Intervention Type
DRUG
Total Trials
29